Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 11/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19995874 | 0.87 | ADORA1 (0.46) | ADORA1PDK4GRM5GRM1NAMPT | |
| SCHEMBL12931062 | 0.79 | ADORA1 (0.53) | ADORA1PDK4GRM5GRM1NAMPT | |
| SCHEMBL10201181 | 0.78 | PDK4 (0.51) | ADORA1PDK4GRM5GRM1NAMPT | |
| SCHEMBL17886544 | 0.77 | ALDH1A1 (0.42) | — | |
| SCHEMBL5392226 | 0.76 | PDK4 (0.46) | ADORA1PDK4GRM5GRM1NAMPT | |
| SCHEMBL8218881 | 0.75 | PDK4 (0.51) | ADORA1PDK4GRM5GRM1NAMPT | |
| SCHEMBL9948004 | 0.75 | ADORA1 (0.49) | ADORA1PDK4GRM5GRM1NAMPT | |
| SCHEMBL146987 | 0.75 | PDK4 (0.45) | ADORA1PDK4GRM5GRM1NAMPT | |
| SCHEMBL31195159 | 0.74 | ADORA1 (0.48) | ADORA1PDK4GRM5GRM1 | |
| SCHEMBL12566963 | 0.74 | PDK4 (0.48) | ADORA1PDK4GRM5GRM1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-12421220-B2 | Bicyclic-substituted glutarimide cereblon binders | C4 THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250122179-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| EP-4536656-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-119325475-A | Bicyclic substituted glutarimide cereblon binders | C4医药公司 | 2025-01-17 | — | — | CN | disclosed |
| WO-2023239750-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | ADORA1 4426/4885PDK4 2552/4885GRM5 1260/4885 |
| US-20250122179-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | ADORA1 4426/4885PDK4 2552/4885GRM5 1260/4885 |
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | ADORA1 4426/4885PDK4 2552/4885GRM5 1260/4885 |
| US-12421220-B2 | Bicyclic-substituted glutarimide cereblon binders | CRBN, STUB1, CUL1 | ADORA1 4426/4885PDK4 2552/4885GRM5 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.